Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of therapy.[1] Data from the study were featured in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting (Abstract #797).“There are currently no comparative clinical trials in first-line CLL among the BTKi class,[1] highlighting the critical need to leverage real-world experience to support optimized treatment selection,” said Ryan Jacobs†, M.D., Clinical Director, Division of Lymphoma Therapy & Research, Department of Hematologic Oncology, Atrium Health Levine Cancer Institute and principal study investigator. “These results demonstrate the possible impact of using ibrutinib versus acalabrutinib in the front-line setting and provide healthcare professionals with additional data showing differences in time to next treatment.”The study used Acentrus‡, de-identified academic electronic medical records (EMR) to i...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news
More News: Academia | Acute Leukemia | Allergy & Immunology | Anemia | Arrhythmia | Atrial Fibrillation | Bilirubin | Biotechnology | Bleeding | Brain | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiac Arrhythmia | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Child Development | Children | Chronic Leukemia | Chronic Lymphocytic Leukemia | Chronic Pain | Clinical Trials | Databases & Libraries | Diabetes | Diabetes Mellitus | Electronic Medical Records (EMR) | Endocrinology | Environmental Health | Food and Drug Administration (FDA) | Gastroenterology | Genetics | Grapefruit | Headache | Health Management | Heart | Hematology | Hodgkin's Disease | Hormones | Hypertension | Infectious Diseases | Laboratory Medicine | Learning | Legislation | Leukemia | Lymphoma | Macroglobulinemia | Melanoma | Migraine | Neurology | Neuroscience | Neurosurgery | Non-Hodgkin's Lymphoma | Nonmelanoma Skin Cancer | Oral Cancer | Oranges | Pain | Pediatrics | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Pregnancy | Primary CNS Lymphoma | Pulmonary Hypertension | Science | Skin | Skin Cancer | Skin Graft | Study | Thrombocytopenia | Toxicology | Universities & Medical Training | Vaccines | Veterinary Vaccinations | Waldenstrom's Macroglobulinemia | Women